smiles

Dentist ,investor

[smiles @doccjc62]

$RDGL Agree!

[RDGL INVESTORS GROUP @RDGLinvestors]

$RDGL Up almost 5% today,,,,,Just getting started.

[smiles @doccjc62]

$RDGL Licensing piece reinforces intent and direction .

[RDGL INVESTORS GROUP @RDGLinvestors]

$RDGL scores a major win: Washington State radioactive materials license secured for domestic IsoPet manufacturing. RadioGel next!

[Vivos Inc. @VivosIncUSA]

Vivos Inc is pleased to announce the receipt of the Washington State Radioactive Materials License for IsoPet® Manufacturing which clears the way for in-house production at Vivos’ new domestic manufacturing facility. $RDGL https://t.co/SYUj8N0IFb

[RDGL INVESTORS GROUP @RDGLinvestors]

$RDGL Still under the radar, but 25 days max may change all of that. Bring on the IDE decision.

[smiles @doccjc62]

$RDGL This one is still under the radar.

[RDGL INVESTORS GROUP @RDGLinvestors]

🚀 $RDGL (Vivos Inc.) – Deeply Undervalued Precision Cancer Therapy Opportunity. 💵💵💵

Current ~$0.061 | ~$30M market cap

Key Catalysts 💰(Near-Term Momentum):

• IDE Submitted on June 5th to the FDA for Early Feasibility human study ✅
→ FDA decision expected in <30 days ⏲️
→ Led by ex-FDA expert Dr. John J. Smith
* Trials at the Mayo Clinic upon IDE approval

• India – Positive human therapy demonstrations with strong safety & tumor response
→ Pursuing expanded approvals (DCGI pathway)

• IsoPet (vet) – Explosive 1,200% YoY growth in 2025 📈
→ 200+ treatments across clinics 📈
→ Excellent real-world safety data

• RadioGel – Injectable Y-90 hydrogel for localized tumor radiation
→ Stays in place, spares healthy tissue
→ FDA Breakthrough Device Designation ✅

• PrecisionGel – Broader hydrogel platform with new patents
→ Strong international licensing potential. 💰💰💰

Vet revenue growing fast + imminent FDA news + licensing upside = very compelling setup right now. 📈
$RDGL $RadioGel $IsoPet $PrecisionGel

[smiles @doccjc62]

$RDGL
✅ IDE for RadioGel resubmitted to the FDA today
✅ Top FDA expert Dr. John J. Smith on board
✅ 30 days or less for decision.
Share price hasn’t moved.....yet....🚀🚀🚀

[Vivos Inc. @VivosIncUSA]

Vivos Inc. (OTCQB: RDGL) submits Early Feasibility Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel® Precision Radionuclide Therapy™ $RDGL https://t.co/00SmrdK0Ob

[smiles @doccjc62]

Let's get that IDE approval ! $RDGL

[Vivos Inc. @VivosIncUSA]

Vivos Inc. (OTCQB: RDGL) submits Early Feasibility Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel® Precision Radionuclide Therapy™ $RDGL https://t.co/00SmrdK0Ob

[RDGL INVESTORS GROUP @RDGLinvestors]

New abstract and presentation from Johns Hopkins, $RDGL https://t.co/5iMqPhxeFJ

[smiles @doccjc62]

$RDGL, once this goes, it's going to run hard imo

[RDGL INVESTORS GROUP @RDGLinvestors]

🚨 $RDGL at $0.065 / $32M MC
Flying Under the Radar! 📈📈📈

Precision Radionuclide Therapy that targets tumors precisely for both humans and pets.

4 KEY CATALYSTS:

FDA IDE SUBMISSION... Imminent filing for RadioGel→ Human trials at Mayo Clinic on approval. Unlocks massive U.S. market potential.

INDIA HUMAN TRIALS... Ongoing demos showing tumor shrinkage + excellent safety (zero serious side effects). Builds strong global credibility.

IsoPet (Veterinary)... 800%+ growth, 100+ treatments, 17+ clinics expanding. Real revenue ramp into 2026.

PrecisionGel... Patented Y-90 hydrogel + new U.S./India plants in 2026. Ready for licensing & partnerships.

CEO owns over 11 million shares with recent buys.... serious skin in the game.

This tiny-cap biotech is loaded with near-term catalysts. Could be a big runner in 2026. 📈📈📈
$RDGL $RadioGel $IsoPet $Biotech

[smiles @doccjc62]

$RDGL @ .065,(32 mil MC) Still under the radar

[RDGL INVESTORS GROUP @RDGLinvestors]

$RDGL (Vivos Inc.) Perfectly Positioned as Solid Tumor Treatment Race Accelerates in Multi-Billion Dollar Oncology Boom.
@VivosIncUSA @RadioGel

https://t.co/31ywohJjt7

[smiles @doccjc62]

Huge potential for PrecisionGel !

[RDGL INVESTORS GROUP @RDGLinvestors]

1/7
PrecisionGel: A Platform Beyond RadioGel?
Vivos Inc. ($RDGL) just dropped new data on PrecisionGel. While everyone’s talking oncology, this could be the start of a versatile controlled-release delivery platform with huge potential across many medical fields.
Educational thread 👇

[smiles @doccjc62]

@VivosIncUSA PrecisionGel.... so much potential for this product. Keep up the good work. Patience will pay off for RDGL's investors.

[smiles @doccjc62]

Nice to have a top FDA expert guiding $RDGL through the IDE process. Let's get that approval !

[RDGL INVESTORS GROUP @RDGLinvestors]

As we wait for the IDE submission, let’s take a look at who is guiding us through the process.

Vivos Inc.(RDGL) is working with Dr. John J. Smith, M.D., J.D. and his team at Hogan Lovells to advance the RadioGel IDE submission.

Dr. Smith’s credentials:
• Board-certified diagnostic radiologist
• Former associate professor at Harvard Medical School
• Partner in Hogan Lovells’ Global Regulatory group (Washington, D.C.)
• Leading FDA expert with extensive hands-on experience on brachytherapy, radiation devices, pre-submissions, IDEs, and PMAs
• Direct familiarity with the FDA Division of Radiological Imaging and Radiation Therapy Devices (the group reviewing our submission)

This level of specialized expertise helps address remaining items and strengthens our application.

We are in excellent hands.
$RDGL #RadioGel #VivosInc #Biotech #SmallCap

[smiles @doccjc62]

“Direct familiarity with the FDA Division of Radiological Imaging and Radiation Therapy Devices (the group reviewing our submission)”. That’s HUGE imo.

[RDGL INVESTORS GROUP @RDGLinvestors]

As we wait for the IDE submission, let’s take a look at who is guiding us through the process.

Vivos Inc.(RDGL) is working with Dr. John J. Smith, M.D., J.D. and his team at Hogan Lovells to advance the RadioGel IDE submission.

Dr. Smith’s credentials:
• Board-certified diagnostic radiologist
• Former associate professor at Harvard Medical School
• Partner in Hogan Lovells’ Global Regulatory group (Washington, D.C.)
• Leading FDA expert with extensive hands-on experience on brachytherapy, radiation devices, pre-submissions, IDEs, and PMAs
• Direct familiarity with the FDA Division of Radiological Imaging and Radiation Therapy Devices (the group reviewing our submission)

This level of specialized expertise helps address remaining items and strengthens our application.

We are in excellent hands.
$RDGL #RadioGel #VivosInc #Biotech #SmallCap

[smiles @doccjc62]

@LauraEstey87438 @VivosIncUSA Late Form 3 for shares owned since last September. No new buy,
Administrative

[smiles @doccjc62]

@LauraEstey87438 @VivosIncUSA The Form 3 is just an initial disclosure of what Brad already owns since becoming President last September. No new purchase or exercise happened on the 28th, so it doesn’t suggest insider trading ahead of news.

[smiles @doccjc62]

@LauraEstey87438 @VivosIncUSA @LauraEstey87438 The India human data is **supportive** (to strengthen the package), but **not required** for the FDA IDE submission. Vivos has always said the paths run in parallel.
We’ll know soon enough who’s right .

[smiles @doccjc62]

@LauraEstey87438 @VivosIncUSA The IDE stands strong on the existing India human data alone…. FDA doesn’t need DCGI approval first. Timing or delays don’t change the promising results.

[smiles @doccjc62]

@LauraEstey87438 @VivosIncUSA No, regulatory paths in different countries run in parallel, not as precursors. Vivos is pushing the U.S. IDE forward while wrapping up India items. Early human data remains promising.

[smiles @doccjc62]

@LauraEstey87438 @VivosIncUSA Good luck to you on your next investment.